Page last updated: 2024-08-21

myristic acid and Atherosclerosis

myristic acid has been researched along with Atherosclerosis in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Binesh, A; Devaraj Sivasitambaram, N; Halagowder, D	1
Ahnström, J; Binder, CJ; Björkbacka, H; Christoffersen, C; Dahlbäck, B; Elsøe, S; Heinecke, JW; Hoofnagle, AN; Nielsen, LB; Plomgaard, P	1
Braam, B; Verhaar, MC	1

Reviews

1 review(s) available for myristic acid and Atherosclerosis

Article	Year
Understanding eNOS for pharmacological modulation of endothelial function: a translational view. Current pharmaceutical design, 2007, Volume: 13, Issue:17 Topics: Animals; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases; Endothelium, Vascular; Gene Expression Regulation, Enzymologic; Guanylate Cyclase; Humans; Kidney Diseases, Cystic; Myristic Acid; Nitric Oxide; Nitric Oxide Synthase Type III; Palmitic Acid; Phosphorylation; Protein Processing, Post-Translational; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Risk Factors; Signal Transduction; Soluble Guanylyl Cyclase	2007

Article

Year

Understanding eNOS for pharmacological modulation of endothelial function: a translational view.

Current pharmaceutical design, 2007, Volume: 13, Issue:17

Topics: Animals; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases; Endothelium, Vascular; Gene Expression Regulation, Enzymologic; Guanylate Cyclase; Humans; Kidney Diseases, Cystic; Myristic Acid; Nitric Oxide; Nitric Oxide Synthase Type III; Palmitic Acid; Phosphorylation; Protein Processing, Post-Translational; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Risk Factors; Signal Transduction; Soluble Guanylyl Cyclase

2007

Other Studies

2 other study(ies) available for myristic acid and Atherosclerosis

Article	Year
Monocytes treated with ciprofloxacin and oxyLDL express myristate, priming atherosclerosis. Journal of biochemical and molecular toxicology, 2020, Volume: 34, Issue:3 Topics: Atherosclerosis; Ciprofloxacin; Gene Expression Regulation; Humans; Lipoproteins, LDL; Monocytes; Myristic Acid; THP-1 Cells	2020
Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis, 2012, Volume: 221, Issue:1 Topics: Amidines; Animals; Antioxidants; Apolipoproteins; Apolipoproteins M; Atherosclerosis; Binding Sites; Cholesterol, Dietary; Disease Models, Animal; Humans; Lipocalins; Lipoproteins, HDL; Lipoproteins, LDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Myristic Acid; Oxidants; Oxidation-Reduction; Phospholipids; Receptors, LDL; Recombinant Proteins; Thiobarbituric Acid Reactive Substances; Time Factors	2012

Article

Year

Monocytes treated with ciprofloxacin and oxyLDL express myristate, priming atherosclerosis.

Journal of biochemical and molecular toxicology, 2020, Volume: 34, Issue:3

Topics: Atherosclerosis; Ciprofloxacin; Gene Expression Regulation; Humans; Lipoproteins, LDL; Monocytes; Myristic Acid; THP-1 Cells

2020

Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL.

Atherosclerosis, 2012, Volume: 221, Issue:1

Topics: Amidines; Animals; Antioxidants; Apolipoproteins; Apolipoproteins M; Atherosclerosis; Binding Sites; Cholesterol, Dietary; Disease Models, Animal; Humans; Lipocalins; Lipoproteins, HDL; Lipoproteins, LDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Myristic Acid; Oxidants; Oxidation-Reduction; Phospholipids; Receptors, LDL; Recombinant Proteins; Thiobarbituric Acid Reactive Substances; Time Factors

2012